Go Pro
LON:NIOX

NIOX Group Interim Earnings Report

NIOX Group logo
GBX 66.80 +0.80 (+1.21%)
As of 12:00 PM Eastern

NIOX Group EPS Results

Actual EPS
GBX 1.43
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

NIOX Group Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

NIOX Group Announcement Details

Quarter
Interim
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

NIOX Group Earnings Headlines

NIOX Group PLC CSSPF
How Elon’s Empire Ends (and how to profit)
Marc Chaikin, the 60 year Wall Street veteran whose Chaikin Money Flow indicator sits on every Bloomberg terminal, says a new micro cluster AI technology could render today's data centers, including Elon Musk's Colossus in Tennessee, obsolete for major breakthroughs. These next generation centers use 99 percent less space, electricity and water, yet Chaikin's research shows they could be more than a trillion times more powerful than the top data center on earth today, potentially cutting AI breakthrough timelines from five years to five days.tc pixel
NIOX Group PLC NIOX
Top UK Penny Stocks To Watch In March 2026
See More NIOX Group Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like NIOX Group? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NIOX Group and other key companies, straight to your email.

About NIOX Group

NIOX Group (LON:NIOX) is a medical technology company focused on improving the lives of millions of people suffering from respiratory health issues globally. NIOX develops and markets innovative, non-invasive diagnostic products for chronic airway diseases, primarily asthma and COPD. Its lead product, NIOX VERO®, enables the accurate measurement of fractional exhaled nitric oxide (FeNO), an established biomarker for airway inflammation, supporting better diagnosis, monitoring and management of asthma and COPD in clinical and research settings. Headquartered in the UK and listed on the London Stock Exchange (ticker: NIOX), the company operates internationally, serving healthcare professionals in over 50 countries. NIOX is committed to enabling more precise and personalised care for patients with respiratory conditions, with a focus on quality, innovation, and scientific excellence.

View NIOX Group Profile